These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 24498545)

  • 1. Clarifying the pharmacodynamics of tecemotide (L-BLP25)-based combination therapy.
    Kao CJ; Wurz GT; Schröder A; Wolf M; Degregorio MW
    Oncoimmunology; 2013 Oct; 2(10):e26285. PubMed ID: 24498545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.
    Butts C; Socinski MA; Mitchell PL; Thatcher N; Havel L; Krzakowski M; Nawrocki S; Ciuleanu TE; Bosquée L; Trigo JM; Spira A; Tremblay L; Nyman J; Ramlau R; Wickart-Johansson G; Ellis P; Gladkov O; Pereira JR; Eberhardt WE; Helwig C; Schröder A; Shepherd FA;
    Lancet Oncol; 2014 Jan; 15(1):59-68. PubMed ID: 24331154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tecemotide: an antigen-specific cancer immunotherapy.
    Wurz GT; Kao CJ; Wolf M; DeGregorio MW
    Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study.
    Rossmann E; Österborg A; Löfvenberg E; Choudhury A; Forssmann U; von Heydebreck A; Schröder A; Mellstedt H
    Hum Vaccin Immunother; 2014; 10(11):3394-408. PubMed ID: 25483677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer.
    Katakami N; Hida T; Nokihara H; Imamura F; Sakai H; Atagi S; Nishio M; Kashii T; Satouchi M; Helwig C; Watanabe M; Tamura T
    Lung Cancer; 2017 Mar; 105():23-30. PubMed ID: 28236981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC).
    Schimanski CC; Kasper S; Hegewisch-Becker S; Schröder J; Overkamp F; Kullmann F; Bechstein WO; Vöhringer M; Öllinger R; Lordick F; Heinemann V; Geißler M; Schulz-Abelius A; Bernhard H; Schön MR; Greil R; Galle P; Lang H; Schmidtmann I; Moehler M
    Oncoimmunology; 2020 Aug; 9(1):1806680. PubMed ID: 32923171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small cell lung cancer (START): a randomized, double-blind, phase III trial.
    DeGregorio M; Soe L; Wolf M
    J Thorac Dis; 2014 Jun; 6(6):571-3. PubMed ID: 24976972
    [No Abstract]   [Full Text] [Related]  

  • 8. L-BLP25: a peptide vaccine strategy in non small cell lung cancer.
    Sangha R; Butts C
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4652-4. PubMed ID: 17671159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34).
    Singer CF; Pfeiler G; Hubalek M; Bartsch R; Stöger H; Pichler A; Petru E; Bjelic-Radisic V; Greil R; Rudas M; Maria Tea MK; Wette V; Petzer AL; Sevelda P; Egle D; Dubsky PC; Filipits M; Fitzal F; Exner R; Jakesz R; Balic M; Tinchon C; Bago-Horvath Z; Frantal S; Gnant M;
    Eur J Cancer; 2020 Jun; 132():43-52. PubMed ID: 32325419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer.
    Butts C; Murray N; Maksymiuk A; Goss G; Marshall E; Soulières D; Cormier Y; Ellis P; Price A; Sawhney R; Davis M; Mansi J; Smith C; Vergidis D; Ellis P; MacNeil M; Palmer M
    J Clin Oncol; 2005 Sep; 23(27):6674-81. PubMed ID: 16170175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial.
    Butts C; Maksymiuk A; Goss G; Soulières D; Marshall E; Cormier Y; Ellis PM; Price A; Sawhney R; Beier F; Falk M; Murray N
    J Cancer Res Clin Oncol; 2011 Sep; 137(9):1337-42. PubMed ID: 21744082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer.
    Stinchcombe TE; Bogart JA
    Oncologist; 2012; 17(5):682-93. PubMed ID: 22531360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer.
    Butts C; Murray RN; Smith CJ; Ellis PM; Jasas K; Maksymiuk A; Goss G; Ely G; Beier F; Soulières D
    Clin Lung Cancer; 2010 Nov; 11(6):391-5. PubMed ID: 21071331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor effects of cisplatin combined with tecemotide immunotherapy in a human MUC1 transgenic lung cancer mouse model.
    Kao CJ; Wurz GT; Monjazeb AM; Vang DP; Cadman TB; Griffey SM; Wolf M; DeGregorio MW
    Cancer Immunol Res; 2014 Jun; 2(6):581-9. PubMed ID: 24894093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
    Eberhardt WE; Pöttgen C; Gauler TC; Friedel G; Veit S; Heinrich V; Welter S; Budach W; Spengler W; Kimmich M; Fischer B; Schmidberger H; De Ruysscher D; Belka C; Cordes S; Hepp R; Lütke-Brintrup D; Lehmann N; Schuler M; Jöckel KH; Stamatis G; Stuschke M
    J Clin Oncol; 2015 Dec; 33(35):4194-201. PubMed ID: 26527789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L-BLP25 as a peptide vaccine therapy in non-small cell lung cancer: a review.
    Xia W; Wang J; Xu Y; Jiang F; Xu L
    J Thorac Dis; 2014 Oct; 6(10):1513-20. PubMed ID: 25364531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. A Southwest Oncology Group trial.
    Rusch VW; Albain KS; Crowley JJ; Rice TW; Lonchyna V; McKenna R; Livingston RB; Griffin BR; Benfield JR
    J Thorac Cardiovasc Surg; 1993 Jan; 105(1):97-104; discussion 104-6. PubMed ID: 8380477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of immunotherapy in stage III nonsmall cell lung cancer.
    Wrona A
    Curr Opin Oncol; 2019 Jan; 31(1):18-23. PubMed ID: 30489337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L-BLP25 vaccine plus letrozole induces a TH1 immune response and has additive antitumor activity in MUC1-expressing mammary tumors in mice.
    Mehta NR; Wurz GT; Burich RA; Greenberg BE; Griffey S; Gutierrez A; Bell KE; McCall JL; Wolf M; DeGregorio M
    Clin Cancer Res; 2012 May; 18(10):2861-71. PubMed ID: 22434666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial.
    Schimanski CC; Möhler M; Schön M; van Cutsem E; Greil R; Bechstein WO; Hegewisch-Becker S; von Wichert G; Vöhringer M; Heike M; Heinemann V; Peeters M; Kanzler S; Kasper S; Overkamp F; Schröder J; Seehofer D; Kullmann F; Linz B; Schmidtmann I; Smith-Machnow V; Gockel I; Lang H; Galle PR
    BMC Cancer; 2012 Apr; 12():144. PubMed ID: 22494623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.